Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 2:3:889221.
doi: 10.3389/falgy.2022.889221. eCollection 2022.

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Louise De Prins  1 , Ulrike Raap  2   3 , Tara Mueller  2   3 , Peter Schmid-Grendelmeier  4 , Christiane H Haase  5 , Vibeke Backer  5 , Wytske Fokkens  6 , Linda B Benoist  6 , Emmanuel Prokopakis  7 , Claire Hopkins  8 , Nele Claeys  1   2   3   4   5   6   7   8   9 , Thijs Teeling  1   2   3   4   5   6   7   8   9 , Lindsay Cypers  1   2   3   4   5   6   7   8   9 , Leen Cools  1   2   3   4   5   6   7   8   9 , Leif H Bjermer  1   2   3   4   5   6   7   8   9 , Zuzana Diamant  1   2   3   4   5   6   7   8   9 , Ulrich Wahn  1   2   3   4   5   6   7   8   9 , Glenis Scadding  1   2   3   4   5   6   7   8   9 , Claus Bachert  9 , Sunni R Patel  1   2   3   4   5   6   7   8   9 , Elizabeth Van Staeyen  1   2   3   4   5   6   7   8   9 , Peter Hellings  1   6   9
Affiliations

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Louise De Prins et al. Front Allergy. .

Erratum in

Abstract

Background: Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases.

Aims: To improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future.

Methodology: This qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach.

Results: Eighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the need for alternatives to sinus surgery, whereas patients with asthma requested better medical care to prevent exacerbations and patients with AD would warmly welcome the reimbursement of emollients.

Conclusion: Patients with asthma, CRSwNP and AD have shared unmet needs that need to be addressed by physicians, the academic community and health policy makers. This survey provides unique recommendations made by patients for the implementation of better care.

Keywords: Type 2 inflammation; asthma; atopic dermatitis; chronic rhinosinusitis; nasal polyps; quality of life; unmet needs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Summary of the burden of Type 2 inflammatory conditions (AD, asthma and CRSwNP), statements ordered by number of times reported.
Figure 2
Figure 2
Overview of the perceived unmet needs of current care for patients with Type 2 inflammation, statements ordered by number of times reported.
Figure 3
Figure 3
Overview of the 4 key shortcomings and suggestions from patients with Type 2 inflammatory diseases.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCormick JP, Lee JT. Insights into the implications of coexisting type 2 inflammatory diseases. J Inflamm Res. (2021) 14:4259–66. 10.2147/JIR.S311640 - DOI - PMC - PubMed
    1. Hassoun D, Malard O, Barbarot S, Magnan A, Colas L. Type 2 immunity-driven diseases: towards a multidisciplinary approach. Clin Exp Allergy. (2021) 51:1538–52. 10.1111/cea.14029 - DOI - PMC - PubMed
    1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. . European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. (2020) 58:1–464. 10.4193/Rhin20.401 - DOI - PubMed
    1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. (2013) 132:1132–8. 10.1016/j.jaci.2013.08.031 - DOI - PubMed
    1. Global Initiative for Asthma,. Global Strategy for Asthma Management Prevention. (2021). Available online at: www.ginasthma.org (accessed December 29, 2021).

LinkOut - more resources